CONTEXT: Sclerostin, a protein encoded by the SOST gene in osteocytes and an antagonist of the Wnt signaling pathway, is down-regulated by PTH administration. Disorders of parathyroid function are useful clinical settings to study this relationship. OBJECTIVE: The objective of the study was to evaluate sclerostin in two different disorders of parathyroid function, primary hyperparathyroidism and hypoparathyroidism, and to analyze the relationship between sclerostin and PTH, bone markers, and bone mineral density. DESIGN: This is a cross-sectional study. SETTING: The study was conducted at a clinical research center. PATIENTS: Twenty hypoparathyroid and 20 hyperparathyroid patients were studied and compared to a reference control group. RESULTS: Serum sclerostin was significantly higher in hypoparathyroid subjects than in hyperparathyroid subjects (P < 0.0001) and controls (P < 0.0001). PTH was negatively associated with sclerostin, achieving statistical significance in hypoparathyroidism (r = -0.545; P = 0.02). The bone turnover markers, cross-linked C-telopeptide of type I collagen (CTX) and amino-terminal propeptide of type I collagen (P1NP), were differently associated with sclerostin according to the parathyroid disorder. In primary hyperparathyroidism, bone turnover markers were associated negatively with sclerostin (for P1NP, r = -0.490; P = 0.03). In hypoparathyroidism, bone turnover markers were associated positively with sclerostin (for CTX, r = +0.571; P = 0.01). Although there was no significant correlation between bone mineral density and sclerostin in either parathyroid disorder, there was a significant positive relationship between sclerostin and bone mineral content in hypoparathyroidism. CONCLUSIONS: The results are consistent with the hypothesis that PTH is a regulator of sclerostin in human disorders of parathyroid function. In addition, the results suggest that bone mineral content may be another factor that influences sclerostin.
CONTEXT: Sclerostin, a protein encoded by the SOST gene in osteocytes and an antagonist of the Wnt signaling pathway, is down-regulated by PTH administration. Disorders of parathyroid function are useful clinical settings to study this relationship. OBJECTIVE: The objective of the study was to evaluate sclerostin in two different disorders of parathyroid function, primary hyperparathyroidism and hypoparathyroidism, and to analyze the relationship between sclerostin and PTH, bone markers, and bone mineral density. DESIGN: This is a cross-sectional study. SETTING: The study was conducted at a clinical research center. PATIENTS: Twenty hypoparathyroid and 20 hyperparathyroidpatients were studied and compared to a reference control group. RESULTS: Serum sclerostin was significantly higher in hypoparathyroid subjects than in hyperparathyroid subjects (P < 0.0001) and controls (P < 0.0001). PTH was negatively associated with sclerostin, achieving statistical significance in hypoparathyroidism (r = -0.545; P = 0.02). The bone turnover markers, cross-linked C-telopeptide of type I collagen (CTX) and amino-terminal propeptide of type I collagen (P1NP), were differently associated with sclerostin according to the parathyroid disorder. In primary hyperparathyroidism, bone turnover markers were associated negatively with sclerostin (for P1NP, r = -0.490; P = 0.03). In hypoparathyroidism, bone turnover markers were associated positively with sclerostin (for CTX, r = +0.571; P = 0.01). Although there was no significant correlation between bone mineral density and sclerostin in either parathyroid disorder, there was a significant positive relationship between sclerostin and bone mineral content in hypoparathyroidism. CONCLUSIONS: The results are consistent with the hypothesis that PTH is a regulator of sclerostin in human disorders of parathyroid function. In addition, the results suggest that bone mineral content may be another factor that influences sclerostin.
Authors: Rutger L van Bezooijen; J Peter Svensson; Daniël Eefting; Annemieke Visser; Geertje van der Horst; Marcel Karperien; Paul H A Quax; Harry Vrieling; Socrates E Papapoulos; Peter ten Dijke; Clemens W G M Löwik Journal: J Bone Miner Res Date: 2007-01 Impact factor: 6.741
Authors: T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka Journal: Endocrinology Date: 2005-08-04 Impact factor: 4.736
Authors: Rutger L van Bezooijen; Peter ten Dijke; Socrates E Papapoulos; Clemens W G M Löwik Journal: Cytokine Growth Factor Rev Date: 2005-06 Impact factor: 7.638
Authors: Kenneth E S Poole; Rutger L van Bezooijen; Nigel Loveridge; Herman Hamersma; Socrates E Papapoulos; Clemens W Löwik; Jonathan Reeve Journal: FASEB J Date: 2005-08-25 Impact factor: 5.191
Authors: Jordan L Geller; Azarmindokht Khosravi; Marilyn H Kelly; Mara Riminucci; John S Adams; Michael T Collins Journal: J Bone Miner Res Date: 2007-06 Impact factor: 6.741
Authors: Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra Journal: Bone Date: 2012-06-15 Impact factor: 4.398
Authors: Sandra Jastrzebski; Judith Kalinowski; Marina Stolina; Faryal Mirza; Elena Torreggiani; Ivo Kalajzic; Hee Yeon Won; Sun-Kyeong Lee; Joseph Lorenzo Journal: J Bone Miner Res Date: 2013-03 Impact factor: 6.741
Authors: Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov Journal: Osteoporos Int Date: 2013-01-29 Impact factor: 4.507